The United Kingdom led the continent in deal making during February, accounting for 25 startups that collectively raised €338.83 million ($374 million) during the month, according to preliminary data from Thomson Reuters.
This included MISSION Therapeutics, a Cambridge, England-based drug discovery and development company focused on treating cancer, neurodegenerative and other diseases. The company raised €79 million ($87 million) led by Imperial Innovations Businesses and including new investor Woodford Patient Capital Trust and existing backers Sofinnova Partners, SR One, Roche Venture Fund and Pfizer Venture Investments.
It was the largest VC-backed financing throughout Europe during February.
However, France was the most active country, with a total of 28 companies based in France having raised €111.2 million ($122 million) in the country during February.
The third most active region behind France and the United Kingdom was Germany, which saw 25 companies raise €92.35 million ($102 million) in February.
Holtzbrinck Ventures GmbH was one of the more active investors in February, backing four companies, including three in Germany and one in the United Kingdom.
A number of U.S.-based investors also got into the act, such as Accel Partners and New Enterprise Associates. One of the companies that raised the most from U.S. investors was London-based QuBit Digital Ltd, which raised €$36 million ($40 million) from Accel Partners, Goldman Sachs & Co, Salesforce Ventures and Sapphire Ventures.
To see the full list of European deals from the month, download an Excel file: European VC-backed deals from February
The table is a compilation of venture capital transactions involving European-based deals announced in February 2016 and is based on Thomson Reuters data.
The listings are sorted by nation.
Photo illustration of euros courtesy of Shutterstock